glp 1 agonist compounding pharmacy The Pharmacist's Guide to GLP-1 and Virtual Prescribing — tl;dr GLP-1 Essential Supplements

No changes in effect sizes were observed when excluding individuals with chronic kidney disease, previous pancreatitis and previous falls

Liraglutide , marketed under the brand name Saxenda, is one such treatment approved for chronic weight management in individuals with a body mass index (BMI) of 30 or higher, or those with a BMI of 27 or higher who have at least one weight-related condition

Kokkorakis M, Chakhtoura M, Rhayem C et al (2025) Emerging pharmacotherapies for obesity: a systematic review

Those with a BMI of 30 or higher (or 27 or higher if you have certain health issues) will benefit

European Teratology Information Services Study (BMJ 2024) Design: Prospective observational cohort Sample: 168 GLP-1 RA-exposed pregnancies, compared with diabetic and obese reference groups Findings: Major birth defect rates: 2.6% (GLP-1 RA) vs